Cambium Bio has raised A$2.12 million through a fully subscribed placement led by Taiwanese institutional investor Da Jyun Capital, supporting the initiation of pivotal Phase 3 trials for its lead ophthalmology candidate.
- A$2.12 million raised via placement of 4.57 million shares at A$0.4637 each
- Placement price represents a 59.9% premium to last closing share price
- Da Jyun Capital Investment Corporation leads with A$2.07 million subscription
- Funds earmarked for Phase 3 trials of Elate Ocular and working capital
- Directors to participate subject to shareholder approval at upcoming AGM
Strategic Capital Raise Bolsters Clinical Progress
Cambium Bio Limited (ASX, CMB), a clinical-stage regenerative medicine company focused on ophthalmology and tissue repair, has successfully completed a fully subscribed placement raising A$2.12 million. The placement involved issuing 4,570,667 new shares at A$0.4637 each, a price that notably reflects a 59.9% premium to the company's last closing price on 29 July 2025.
The capital raise was led by Da Jyun Capital Investment Corporation (DJCIC), a Taiwanese investment firm with deep expertise in regenerative medicine across the Asia-Pacific region. DJCIC subscribed for 4,455,717 shares, contributing A$2.07 million and becoming a cornerstone institutional investor. This strategic partnership not only strengthens Cambium Bio’s shareholder base but also aligns with its long-term clinical and commercial ambitions.
Funding the Next Phase of Innovation
The proceeds from the placement will primarily support the initiation of registration-enabling Phase 3 clinical trials for Cambium Bio’s lead product candidate, Elate Ocular®. This biologic therapy targets significant unmet needs in dry eye disease, a condition affecting millions worldwide. The company also plans to allocate funds toward general working capital to maintain operational momentum.
Directors Professor Edmund K. Waller and Terence A. Walts have indicated their intention to participate in the placement, subscribing for 60,000 and 54,950 shares respectively. However, their participation remains subject to shareholder approval at the upcoming 2025 Annual General Meeting, introducing a slight element of uncertainty regarding the final shareholder composition.
Market Confidence and Future Outlook
CEO Karolis Rosickas expressed optimism about attracting sophisticated institutional investors like DJCIC, highlighting the premium placement price as a strong vote of confidence in Elate Ocular’s intrinsic value and future potential. The company is poised to commence dosing of the first patients in its Phase 3 trials and anticipates initiating global licensing discussions with major pharmaceutical companies and strategic partners.
This capital raise marks a pivotal moment for Cambium Bio, signaling both market validation and a clear pathway toward commercialisation of its regenerative medicine pipeline. Investors will be watching closely for updates on clinical progress and partnership developments in the coming months.
Bottom Line?
Cambium Bio’s successful placement at a significant premium sets the stage for critical Phase 3 trials and potential global partnerships.
Questions in the middle?
- Will director participation be approved at the upcoming AGM, and how might this affect shareholder dynamics?
- What is the timeline for initiating and completing the Phase 3 trials for Elate Ocular?
- When can investors expect updates on licensing discussions with big pharma partners?